Kenvue Option Alert: Sep 19 $25 Calls at the Bid: 55264 vs 58949 OI; Earnings 5/6 Before Open [est] 

Kenvue Option Alert: Sep 19 $25 Calls at the Bid: 55264 @ $1.3 vs 58949 OI; Earnings 5/6 Before Open [est] Ref=$23.86

Kenvue (NYSE:KVUE) Bolsa

Kenvue

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Equities

News

Markets

AVGO

KVUE

MRVL

NVDA

QRVO

RIOT

SWKS

Starboard adquiere 7,7% de Qorvo y podría implementar cambios operativos tras su caída en el mercado de chips.

Qorvo (QRVO) recibe inversión de 500 millones de Starboard tras caída del 28% en sus acciones

Kenvue Inc

Goldman Sachs analyst Kate McShane maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Buy and lowers the price target from $44 to $43.

Price Target

Analyst Ratings

BBWI

Goldman Sachs Maintains Buy on Bath & Body Works, Lowers Price Target to $43

Chardan Capital analyst Daniil Gataulin maintains uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Buy and maintains $38 price target.

QURE

Chardan Capital Maintains Buy on uniQure, Maintains $38 Price Target

D. Boral Capital analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) with a Buy and maintains $12 price target.

CLGN

D. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $12 Price Target

Wolfe Research analyst Mike Polark initiates coverage on Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Outperform rating and announces Price Target of $20.

Initiation

BBNX

Wolfe Research Initiates Coverage On Beta Bionics with Outperform Rating, Announces Price Target of $20

HP Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) shares have fallen 10% this week to $24.56, including a 0.14% drop on Friday. On Wednesday, the company reported mixed second-quarter earnings and cut its outlook.
What To Know: While HP&#8217;s <a href="https://www.benzinga.com/news/earnings/25/05/45659418/hp-stock-tumbles-as-q2-earnings-fall-short-of-estimates-guidance-comes-in-soft-due-to-higher-costs-related-to-tariffs">revenue</a> for the quarter came in at $13.22 billion, slightly ahead of analyst estimates of $13.15 billion, the company missed on earnings, posting adjusted EPS of 71 cents versus the expected 80 cents. 
CEO Enrique Lores highlighted strong commercial performance in the Personal Systems division but noted challenges from a "dynamic regulatory environment," including increased costs due to U.S. tariffs.
Looking ahead, HP guided for third-quarter earnings of 68 cents to 80 cents per share, well below analysts' 90 cent forecast. It also slashed its full-year earnings outlook from a range of $3.45–$3.75 to $3.00–$3.30 per share.
Analyst sentiment turned <a href="https://www.benzinga.com/25/05/45674650/these-analysts-slash-their-forecasts-on-hp-following-downbeat-earnings">more cautious</a> following the results. JPMorgan cut its price target from $30 to $27 while maintaining an Overweight rating. Barclays lowered its target from $36 to $28 and reiterated an Equal-Weight rating.
The disappointing earnings and guidance have weighed heavily on HP shares, which now trade near their lowest levels since early 2023.
Read Also: <a href="https://www.benzinga.com/cannabis/25/05/45693219/feds-favorite-inflation-gauge-slows-but-trumps-china-accusation-flips-market-mood">Fed&#8217;s Favorite Inflation Gauge Slows, But Trump&#8217;s China Accusation Flips Market Mood</a>
<h2 class="wp-block-heading">How To Buy HPQ Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in HP&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, HPQ has a 52-week high of $39.80 and a 52-week low of $21.21.

HP Stock Drops 10% Post-Earnings Miss, Outlook Disappoints

AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) has outperformed the market over the past 5 years by 8.85% on an annualized basis producing an average annual return of 22.68%. Currently, AZZ has a market capitalization of $2.71 billion. 
Buying $1000 In AZZ: If an investor had bought $1000 of AZZ stock 5 years ago, it would be worth $2,855.84 today based on a price of $90.57 for AZZ at the time of writing.
<h3>AZZ's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748619044_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In AZZ 5 Years Ago Would Be Worth This Much Today

PTNM

Pitanium Shares Halted On Circuit Breaker To The Upside At $4.78/Share

Company Launches Far-Reaching Bitcoin Treasury Strategy
SARASOTA, Fla., May 30, 2025 (GLOBE NEWSWIRE) -- Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: <a href="https://www.benzinga.com/stock/djt#Nasdaq,%20NYSE%20Texas">DJT</a>) ("Trump Media" or the "Company"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, announced today that it has closed its previously announced private placement offering ("the Offering") with approximately 50 institutional investors.
The Offering consisted of the sale of (i) 55,857,181 shares of the Company's common stock, at a price of $25.72 per share, for gross proceeds of approximately $1.44 billion and (ii) 0.00% convertible senior secured notes due 2028 in the principal amount of $1.00 billion, at the conversion price of $34.72 per share, for an aggregate purchase price of approximately $2.44 billion. Trump Media will use the approximately $2.32 billion in net proceeds from the Offering to create a Bitcoin treasury and for other general corporate purposes and working capital.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Trump Media Launches Bitcoin Treasury Strategy, After Closing $2.44B Private Placement With Institutional Investors

Despite years of positioning as "digital gold," Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) swift drop below $105,000 reveals a sobering truth: the asset still trades like high-beta tech, not a geopolitical hedge, though experts believe <a href="https://www.benzinga.com/markets/25/05/45602696/more-americans-now-hold-bitcoin-than-gold-report-says">a shift may be underway.</a>
What Happened: After President Donald Trump on Friday <a href="https://truthsocial.com/@realDonaldTrump/posts/114596705340367716">declared</a> on Truth Social that China had "totally violated" its trade agreement and warned that the U.S. is "no longer Mr. Nice Guy," markets responded swiftly.
Equities sold off, and Bitcoin, which had traded above $109,000 on Tuesday, retreated below $105,000 on early Friday.
That reaction prompted analysts and industry leaders to weigh in on what the move says about crypto's current and future position in institutional portfolios.
"Bitcoin's sharp drop underscores its sensitivity to macro shocks, challenging its narrative as a reliable hedge," Andy Lian, intergovernmental blockchain advisor and author, told Benzinga.
Lian acknowledged Bitcoin's growing appeal as a hedge against currency debasement and geopolitical instability but emphasized its continued volatility. 
Also Read: <a href="https://www.benzinga.com/cannabis/25/05/45692508/trump-administration-eyes-strategic-bitcoin-reserve-as-part-of-us-market-infrastructure-overhaul">Trump Administration Eyes Strategic Bitcoin Reserve As Part Of US Market Infrastructure Overhaul</a>
"It still dances to the tune of broader risk sentiment, correlating with equities during stress events," he noted, adding that institutional adoption remains hesitant due to these large price swings.
Speaking with Benzinga, Lingling Jiang, partner at DWF Labs, echoed the sentiment. "Bitcoin dropped to three-week lows after Trump's tariffs on China and others. That tells us crypto is still very much trading as a risk-on asset," she said. 
While Bitcoin is frequently touted as a hedge against inflation or global instability, Jiang said the data points in another direction: "Institutional flows still treat it like a high-beta tech play."
Why It Matters: Both experts believe the current volatility may actually signal a turning point, not a failure.
"Markets are trying to figure out what Bitcoin's role should be in a world where trade wars are becoming the norm," said Jiang. 
She believes this period of uncertainty could ultimately solidify Bitcoin's position as a strategic hedge, particularly if repeated geopolitical shocks normalize its use as a store of value.
Lian also pointed to a growing sentiment shift abroad. 
He cited a recent Chinese academic article, republished by the International Monetary Institution, which frames Bitcoin as a potential "strategic reserve asset." 
While not official policy, it suggests a possible rethinking of crypto's role even in traditionally skeptical jurisdictions.
Still, volatility remains the biggest hurdle. 
"Retail investors may accept the risk, but institutions—pensions, endowments—crave predictability," Lian said, noting that some may prefer gold or stablecoins until Bitcoin's swings stabilize.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45691518/110m-wiped-out-bitcoin-whale-trader-gets-burned-as-btc-tags-104150">$110M Wiped Out: Bitcoin Whale Trader Gets Burned As BTC Tags $104,150</a></li>
</ul>
Image: Shutterstock

Bitcoin Drops To $105,000 After Trump Warns He's 'No Longer Mr. Nice Guy'

Scotiabank analyst Patrick Colville maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Sector Outperform and raises the price target from $242 to $310.

Scotiabank Maintains Sector Outperform on Zscaler, Raises Price Target to $310

Shares of Galaxy Digital Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#NASDAQ">GLXY</a>) fell 5.65% to $18.49 during Friday trading after the company announced an increase in the size of its underwritten public offering.
What To Know: The digital asset and infrastructure firm <a href="https://www.benzinga.com/pressreleases/25/05/n45685251/galaxy-digital-inc-announces-pricing-of-its-upsized-public-offering-of-common-stock">priced</a> 31.6 million Class A common shares at $19.00 each, up from a previously announced 29 million shares. The offering includes 26.4 million shares from Galaxy and 5.2 million from existing shareholders.
Underwriters have a 30-day option to purchase up to 4.74 million additional secondary shares. The offering is expected to close on June 3, pending customary conditions.
Proceeds from Galaxy's <a href="https://www.benzinga.com/pressreleases/25/05/n45685251/galaxy-digital-inc-announces-pricing-of-its-upsized-public-offering-of-common-stock">portion of the sale</a> will be used to acquire newly issued units from its operating subsidiary, Galaxy Digital Holdings LP, which will allocate the funds toward expanding its AI and high-performance computing infrastructure at the Helios data center in West Texas, along with general corporate purposes. Galaxy will not receive proceeds from shares sold by existing shareholders.
Goldman Sachs, Jefferies and Morgan Stanley lead the joint book-running efforts for the offering, with multiple additional financial firms acting as co-managers.
Read Also: <a href="https://www.benzinga.com/cannabis/25/05/45693219/feds-favorite-inflation-gauge-slows-but-trumps-china-accusation-flips-market-mood">Fed&#8217;s Favorite Inflation Gauge Slows, But Trump&#8217;s China Accusation Flips Market Mood</a>
<h2 class="wp-block-heading">How To Buy GLXY Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Galaxy Digital&#8217;s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, GLXY has a 52-week high of $35.30 and a 52-week low of $11.27.
Image: Shutterstock

GLXY

Galaxy Digital (GLXY) Shares Slide 5% Following Upsized Public Offering Announcement

Scotiabank analyst Ben Isaacson maintains Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) with a Sector Outperform and lowers the price target from $50 to $45.

Scotiabank Maintains Sector Outperform on Sociedad Quimica Y Minera, Lowers Price Target to $45

Scotiabank analyst Mike Rizvanovic maintains Royal Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RY#TSX">RY</a>) with a Sector Outperform and lowers the price target from C$188 to C$186.

TSX:RY

Scotiabank Maintains Sector Outperform on Royal Bank of Canada, Lowers Price Target to C$186

<a href="https://www.cnet.com/tech/services-and-software/victorias-secret-takes-down-us-website-after-security-incident/" title="https://www.cnet.com/tech/services-and-software/victorias-secret-takes-down-us-website-after-security-incident/">https://www.cnet.com/tech/services-and-software/victorias-secret-takes-down-us-website-after-security-incident/</a>

VSCO

'Victoria's Secret U.S. Website Back Up After Security Incident; The Lingerie Retailer Briefly Took Down Its Site Earlier This Week As A Security Precaution' - CNET

<a href="https://www.bloomberg.com/news/articles/2025-05-30/microsoft-s-zenimax-reaches-contract-deal-union-says?srnd=homepage-americas&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-30/microsoft-s-zenimax-reaches-contract-deal-union-says?srnd=homepage-americas&amp;embedded-checkout=true</a>

General

MSFT

'Microsoft's ZeniMax Reaches Contract Deal, Union Says'- Bloomberg

IPOs

Pitanium IPO Shares Open For Trade At $4.51/Share; IPO Priced At $4/Share On 1.75M Shares

Scotiabank analyst Nick Altmann maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Sector Perform and raises the price target from $12 to $13.

PATH

Scotiabank Maintains Sector Perform on UiPath, Raises Price Target to $13

<ul>
<li>Trump expected to nominate Lieutenant General Grynkewich</li>
<li>Grynkewich would serve as Supreme Allied Commander Europe</li>
<li>Trump privately communicated decision to NATO's Rutte</li>
<li>Move quells allies' fears that US would relinquish post</li>
</ul>
WASHINGTON/BRUSSELS, May 30 (Reuters) - President <a href="https://www.reuters.com/world/us/donald-trump/">Donald Trump</a> will maintain the traditional role of a U.S. general at the helm of NATO, at least for now, three U.S. officials, a Western official and a NATO source said, even as Washington pushes European allies to take more responsibility for their security.
Trump himself privately communicated the decision to NATO Secretary General Mark Rutte, the Western official said, speaking on condition of anonymity.
The Pentagon, White House and NATO did not immediately respond to requests for comment.
The decision will relieve European NATO allies and even some of Trump's fellow Republicans amid concerns that Washington's tough talk on Europe, and skepticism about the war in Ukraine, could signal a swift retrenchment in America's military leadership.
Still, officials say U.S. warnings that Trump's administration needs to shift its focus to Asia and homeland security are sincere. While no decisions have been made, Trump's administration has discussed possible troop reductions in Europe, where about 80,000 U.S. personnel are based today.
The next expected U.S. nominee for the positions of both Supreme Allied Commander Europe (SACEUR) and U.S. European Command (EUCOM) is Air Force Lieutenant General Alexus Grynkewich, the U.S. officials said.
The U.S. officials spoke on condition of anonymity ahead of an announcement expected in the coming days.
The position of SACEUR, which oversees all NATO operations in Europe, has been filled by a U.S. general since its creation after World War Two. U.S. Army General Dwight D. Eisenhower became the alliance's first SACEUR in 1951.
Since taking office in January, Trump's administration has pressured Europe to ramp up its own defense spending, saying Europe should be primarily responsible for defense on the European continent.
How quickly Europe assumes such a role remains a big question, and there have been discussions within the administration about the possibility of handing over the job of Supreme Allied Commander Europe to a European nation, officials say.
"Make no mistake: President Trump will not allow anyone to turn Uncle Sam into 'Uncle Sucker'," U.S. Defense Secretary Pete Hegseth <a href="reuters://REALTIME/verb=NewsStory/ric=nL1N3P40W2">told reporters</a> during a visit to NATO headquarters in February.
During Trump's first term, maintaining NATO and the leading U.S. role in the alliance was a top priority for his Pentagon chiefs. Retired Marine Corps General Jim Mattis, his first defense secretary, resigned in part because of Trump's skepticism towards NATO.
While the United States was still expected to pressure Europe to do more, and could in the future start redirecting U.S. troops elsewhere as part of a broader review of U.S. deployments, the U.S. decision to maintain the role of SACEUR is certain to be welcomed by key allies of Trump in Congress.
The two Republican lawmakers who lead the Pentagon's oversight committees in the U.S. Congress issued a <a href="reuters://REALTIME/verb=NewsStory/ric=nL1N3Q21CF">rare joint statement</a> in March expressing alarm about a potential U.S. withdrawal from the SACEUR command structure.
Grynkewich, who is now the director for operations at the U.S. military's Joint Staff, would succeed Army General Christopher Cavoli, who has been in the role since shortly after Russia's 2022 invasion of Ukraine, helping oversee billions of dollars in U.S. security assistance to Kyiv.
Trump entered office in January predicting he would be able to end the war in Ukraine in 24 hours. In the months since, he has found that the conflict is more intractable than he believed and has blamed his predecessor, Joe Biden, for allowing it to happen.

Macro Economic Events

Politics

Global

Economics

'U.S. Will Not Relinquish Role Of NATO's Supreme Allied Commander When It Nominates The Next Top U.S. General For Europe; Western Official Says Trump Himself Communicated The Decision To NATO Secretary General Mark Rutte' - Reuters Exclusive

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 5 years by 26.38% on an annualized basis producing an average annual return of 40.21%. Currently, Corcept Therapeutics has a market capitalization of $8.22 billion. 
Buying $1000 In CORT: If an investor had bought $1000 of CORT stock 5 years ago, it would be worth $5,118.73 today based on a price of $77.56 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748618113_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CORT

Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today

Scotiabank analyst Patrick Colville maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Sector Outperform and lowers the price target from $137 to $95.

ESTC

Scotiabank Maintains Sector Outperform on Elastic, Lowers Price Target to $95

Press Releases

Neutrogena® and John Cena Team Up for the Ultimate Disappearing Act in New Ultra Sheer ® Mineral Sunscreen Campaign

OGX® Haircare Introduces Shay Mitchell as First Global Brand Ambassador

Legal

KENVUE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Kenvue Inc. (NYSE: KVUE) and Encourages Long-Term KVUE Investors to Contact the Firm

Kenvue Announces 5-Year Collaboration with Microsoft to Transform Digital Operations

Kenvue Declares Quarterly Cash Dividend

Kenvue to Announce First Quarter 2025 Results on May 8, 2025

Kenvue Announces Chief Financial Officer Transition

Kenvue Reports First Quarter 2025 Results

Everyday Care in Action: Thousands of Kenvue Employees Come Together Across 21 Markets to Help Advance Healthier Communities

Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference

AXIL Brands

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Honest Co

Interparfums

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Entertainment

The Beauty Health Company - Class A Common Stock

Beauty Health

United-Guardian

Unilever

Upexi

Usana Health Sciences

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Comments

Kenvue

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL